These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33579550)

  • 1. Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients.
    O'Leary JG; Philippe A; Freeman R; Heidecke H; Jennings LW; Catar R; Klintmalm GB; Dragun D
    Transplant Proc; 2021 Apr; 53(3):1019-1024. PubMed ID: 33579550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
    El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
    Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Zmonarski S; Mazanowska O; Krajewska M; Bartoszek D; Zabińska M; Myszka M; Kamińska M; Hałoń A; Dawiskiba T; Szyber P; Sas A; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2618-21. PubMed ID: 25380879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome.
    Reinsmoen NL; Mirocha J; Ensor CR; Marrari M; Chaux G; Levine DJ; Zhang X; Zeevi A
    Transplantation; 2017 Jun; 101(6):1215-1221. PubMed ID: 27973391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-HLA Antibodies to G Protein-coupled Receptors in Pediatric Kidney Transplant Recipients: Short- and Long-term Clinical Outcomes.
    Pearl MH; Chen L; Zuckerman JE; Weng PL; Chambers ET; Zhang Q; Reed EF
    Transplantation; 2024 Jan; 108(1):276-283. PubMed ID: 37527494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of angiotensin II type-1 receptor antibodies and endothelin-1 type-A receptor antibodies correlate with antibody-mediated rejection and poor graft function in kidney-transplantation patients.
    Liu C; Kang ZY; Yin Z; Xiao Y; Liu W; Zhao Y; Li DH
    Transpl Immunol; 2022 Oct; 74():101674. PubMed ID: 35901953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Krajewska M; Mazanowska O; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Nowakowska B; Hałoń A; Dawiskiba T; Chudoba P; Klinger M
    Transpl Immunol; 2014 Jan; 30(1):24-9. PubMed ID: 24184747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis.
    Budding K; van de Graaf EA; Hoefnagel T; Kwakkel-van Erp JM; van Kessel DA; Dragun D; Hack CE; Otten HG
    J Cyst Fibros; 2015 Jan; 14(1):42-5. PubMed ID: 25096855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts.
    OʼLeary JG; Demetris AJ; Philippe A; Freeman R; Cai J; Heidecke H; Smith C; Hart B; Jennings LW; Catar R; Everly M; Klintmalm GB; Dragun D
    Transplantation; 2017 Oct; 101(10):2399-2409. PubMed ID: 28665894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
    Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
    Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients.
    Günther J; Kill A; Becker MO; Heidecke H; Rademacher J; Siegert E; Radić M; Burmester GR; Dragun D; Riemekasten G
    Arthritis Res Ther; 2014 Mar; 16(2):R65. PubMed ID: 24612997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-transplant AT
    Gareau AJ; Wiebe C; Pochinco D; Gibson IW; Ho J; Rush DN; Nickerson PW
    Transpl Immunol; 2018 Feb; 46():29-35. PubMed ID: 29217423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies.
    Pearl MH; Leuchter RK; Reed EF; Zhang Q; Ettenger RB; Tsai EW
    Pediatr Nephrol; 2015 Aug; 30(8):1371-4. PubMed ID: 25956702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.
    Lee J; Huh KH; Park Y; Park BG; Yang J; Jeong JC; Lee J; Park JB; Cho JH; Lee S; Ro H; Han SY; Kim MS; Kim YS; Kim SJ; Kim CD; Chung W; Park SB; Ahn C;
    Nephrol Dial Transplant; 2017 Jul; 32(7):1244-1250. PubMed ID: 26546592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA.
    Bankamp L; Preuß B; Pecher AC; Beucke N; Henes J; Klein R
    Front Immunol; 2021; 12():786039. PubMed ID: 34956217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies.
    Civieri G; Iop L; Tona F
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation.
    Hiemann NE; Meyer R; Wellnhofer E; Schoenemann C; Heidecke H; Lachmann N; Hetzer R; Dragun D
    Transplantation; 2012 Nov; 94(9):919-24. PubMed ID: 23034559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria.
    Abuzeineh M; Aala A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 Jul; 21(1):253. PubMed ID: 32615995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.